



June 3, 2021

Marisa L. Cruz, MD  
EVP, Regulatory and Clinical Affairs  
Everlywell, Inc.  
823 Congress Avenue  
Austin, TX 78701

Device: Everlywell COVID-19 Test Home Collection Kit

EUA Number: EUA200283

Company: Everlywell, Inc.

Indication: For use to collect anterior nasal (nasal) swab specimens at home from individuals age 18 years or older (self-collected), 16 years and older (self-collected under adult supervision), or 2 years and older (collected with adult assistance) when determined to be appropriate by a healthcare provider and only for use in molecular diagnostic testing performed using an in vitro diagnostic (IVD) test for the detection of SARS-CoV-2 RNA that is indicated for use with the Everlywell COVID-19 Home Collection Kit.

Authorized Laboratories: Testing is limited to laboratories designated by Everlywell, Inc. that are certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, and meet the requirements to perform high complexity tests and that run the specimens collected from the Everlywell COVID-19 Test Home Collection Kit on an IVD molecular test that is indicated for use with the Everlywell COVID-19 Test Home Collection Kit when used consistent with its authorization.

Dear Dr. Cruz,:

On May 15, 2020, based on your<sup>1</sup> request that Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for emergency use of the Everlywell COVID-19 Test Home Collection Kit,<sup>2</sup> pursuant to Section 564 of the Federal Food, Drug, and Cosmetic Act

---

<sup>1</sup> For ease of reference, this letter will use the term “you” and related terms to refer to Everlywell, Inc.

<sup>2</sup> The May 15, 2020, letter authorized the Everlywell COVID-19 Test Home Collection Kit for use by individuals to self-collect nasal swab specimens at home, when determined by a healthcare provider to be appropriate based on results of a COVID-19 questionnaire, and for use only with in vitro diagnostic (IVD) molecular tests for the detection of SARS-CoV-2 RNA that are indicated for use with the Everlywell COVID-19 Home Collection Kit. Testing was limited to laboratories designated by Everlywell, Inc. that are certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity tests and that run the

(the Act) (21 U.S.C. §360bbb-3). Based on your request, FDA also granted updates to the authorized labeling on September 4, 2020.<sup>3</sup>

On February 16, 2021, and March 19, 2021, FDA received requests from you to amend your EUA. In response to these requests, and having concluded that revising the May 15, 2020, EUA is appropriate to protect the public health or safety under section 564(g)(2)(C) of the Act (21 U.S.C. § 360bbb-3(g)(2)(C)), FDA is reissuing the May 15, 2020, letter in its entirety with the amendments incorporated<sup>4</sup> to authorize the emergency use of your product.<sup>5</sup> Pursuant to section 564 of the Act, Scope of Authorization (Section II) and Conditions of Authorization (Section IV) of this reissued letter, your product is now intended for the indication above.

On February 4, 2020, pursuant to section 564(b)(1)(C) of the Federal Food, Drug, and Cosmetic Act (the Act), the Secretary of the Department of Health and Human Services (HHS) determined that there is a public health emergency that has a significant potential to affect national security or the health and security of United States citizens living abroad, and that involves the virus that causes COVID-19.<sup>6</sup> Pursuant to section 564 of the Act, and on the basis of such determination, the Secretary of HHS then declared on March 24, 2020, that circumstances exist justifying the authorization of emergency use of medical devices during the COVID-19 outbreak, subject to the terms of any authorization issued under that section.<sup>7</sup>

FDA considered the totality of scientific information available in authorizing the emergency use of your product for the indication above. A summary of the performance information FDA relied upon is contained in the EUA Summary (identified below).

Having concluded that the criteria for issuance of this authorization under Section 564(c) of the

---

specimens collected from the Everlywell COVID-19 Test Home Collection Kit on an in vitro diagnostic (IVD) molecular test that is indicated for use with the Everlywell COVID-19 Test Home Collection Kit for self-collection of nasal swab specimens.

<sup>3</sup> On September 4, 2020, your request was granted to update the EUA Summary of the Everlywell COVID-19 Test Home Collection Kit to: (1) include additional distributors, (2) modify the inclusion and exclusion criteria for the use of the device, and (3) add language describing COVID-19 and disease risk factors to the on-line test purchasing website.

<sup>4</sup> The revisions to the May 15, 2020, letter and authorized labeling include (1) updates to the intended use to expand collection of anterior nasal (nasal) swab specimens at home to individuals age 18 years or older (self-collected), 16 years and older (self-collected under adult supervision), or 2 years and older (collected with adult assistance) and to reflect language used in more recent authorizations, (2) updates to the EUA Summary to include results of a human usability study in minors, (3) remove reference to the questionnaire to determine eligibility for the testing and clarifications to the medical oversight and process use, as described in the EUA Summary, (4) removal of Condition P. and Q (from the May 15, 2020, letter) which was fulfilled, and (5) updating the conditions of authorization to add requirement for submission of a 30-day report (P. below) as a result of the new intended use, add new Condition L, M, N below related to good manufacturing practices, consolidation of several conditions in new condition K, and to reflect language used in more recent authorizations.

<sup>5</sup> For ease of reference, this letter will use the term “your product” to refer to the Everlywell COVID-19 Test Home Collection Kit used for the indication identified above.

<sup>6</sup> U.S. Department of Health and Human Services, *Determination of a Public Health Emergency and Declaration that Circumstances Exist Justifying Authorizations Pursuant to Section 564(b) of the Federal Food, Drug, and Cosmetic Act*, 21 U.S.C. § 360bbb-3. 85 FR 7316 (February 7, 2020).

<sup>7</sup> U.S. Department of Health and Human Services, *Declaration that Circumstances Exist Justifying Authorizations Pursuant to Section 564(b) of the Federal Food, Drug, and Cosmetic Act*, 21 U.S.C. § 360bbb-3. 85 FR 17335 (March 27, 2020)

Act are met, I am authorizing the emergency use of your product, described in the Scope of Authorization Section of this letter (Section II), subject to the terms of this authorization.

## **I. Criteria for Issuance of Authorization**

I have concluded that the emergency use of your product meets the criteria for issuance of an authorization under Section 564(c) of the Act, because I have concluded that:

1. The SARS-CoV-2 can cause a serious or life-threatening disease or condition, including severe respiratory illness, to humans infected by this virus;
2. Based on the totality of scientific evidence available to FDA, it is reasonable to believe that your product may be effective in diagnosing COVID-19 by serving as an appropriate means to collect and transport human specimens so that an authorized laboratory can detect SARS-CoV-2 RNA from the home-collected human specimen, and that the known and potential benefits of your product when used for such use, outweigh the known and potential risks of your product; and
3. There is no adequate, approved, and available alternative to the emergency use of your product.<sup>8</sup>

## **II. Scope of Authorization**

I have concluded, pursuant to Section 564(d)(1) of the Act, that the scope of this authorization is limited to the indication above.

### **Authorized Product Details**

Your product is a home collection kit intended for use to collect anterior nasal (nasal) swab specimens a home from individuals age 18 years or older (self-collected), 16 years and older (self-collected under adult supervision), or 2 years and older (collected with adult assistance) when determined to be appropriate by a healthcare provider. Nasal swab specimens collected using your product are transported at ambient temperature for testing at an authorized laboratory. SARS-CoV-2 RNA from the nasal swabs is maintained in the specimen packaging and is only for use in molecular diagnostic testing performed using an in vitro diagnostic (IVD) test for the detection of SARS-CoV-2 RNA that is indicated for use with the the Everlywell COVID-19 Test Home Collection Kit.

When using your product, individuals must follow all specimen collection and mailing instructions provided with the kit. The Everlywell COVID-19 Test Home Collection Kit includes the following materials or other authorized materials: poly mailer, 2D barcode label, nasal swab, transport medium kit, kit ID stickers, return box, UN3373 label, medium alcohol prep pad, absorbent sheet, small biohazard bag, inner box tray, help and contact number insert, shipping and preparation instructions, collection instructions, welcome panel with kit ID, white tray, and return shipping label.

---

<sup>8</sup> No other criteria of issuance have been prescribed by regulation under Section 564(c)(4) of the Act.

Testing is limited to laboratories designated by Everlywell that are certified under the CLIA, 42 U.S.C. §263a, and meet the requirements to perform high complexity tests and that run the specimens collected from your product on an IVD molecular test that is indicated for use with your product when used consistent with its authorization.

The above described product, is authorized to be accompanied with authorized labeling (available at <https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas>). Authorized labeling includes the following documents: EUA Summary, Everlywell COVID-19 Test Home Collection Kit Instructions, and the Receiving and Processing Everlywell Samples standard operating procedure.

The above described product, when accompanied by the authorized labeling (identified above) is authorized to be distributed to and used by individuals (accompanied only by the Everlywell COVID-19 Test Home Collection Kit Instructions) and authorized laboratories (accompanied by all authorized labeling) as set forth in this letter and pursuant to the conditions in this EUA, despite the fact that it does not meet certain requirements otherwise required by applicable federal law.

I have concluded, pursuant to Section 564(d)(2) of the Act, that it is reasonable to believe that the known and potential benefits of your product, when used to diagnose COVID-19 by serving as an appropriate means to collect and transport human specimens so that an authorized laboratory can detect SARS-CoV-2 RNA from the home-collected human specimen, and used consistent with the Scope of Authorization of this letter (Section II), outweigh the known and potential risks of your product for such use.

I have concluded, pursuant to Section 564(d)(3) of the Act, based on the totality of scientific evidence available to FDA, that it is reasonable to believe that your product may be effective in diagnosing COVID-19 by serving as an appropriate means to collect and transport human specimens so that an authorized laboratory can detect SARS-CoV-2 RNA from the home-collected human specimen when used consistent with the Scope of Authorization of this letter (Section II), pursuant to Section 564(c)(2)(A) of the Act.

FDA has reviewed the scientific information available to FDA, including the information supporting the conclusions described in Section I above, and concludes that your product (as described in the Scope of Authorization of this letter (Section II)) meets the criteria set forth in Section 564(c) of the Act concerning safety and potential effectiveness.

The emergency use of your product under this EUA must be consistent with, and may not exceed, the terms of this letter, including the Scope of Authorization (Section II) and the Conditions of Authorization (Section IV). Subject to the terms of this EUA and under the circumstances set forth in the Secretary of HHS's determination under Section 564(b)(1)(C) of the Act described above and the Secretary of HHS's corresponding declaration under Section 564(b)(1) of the Act, your product is authorized for the indication above.

### **III. Waiver of Certain Requirements**

I am waiving the following requirements for your product during the duration of this EUA:

- Current good manufacturing practice requirements, including the quality system requirements under 21 CFR Part 820 with respect to the design, manufacture, packaging, labeling, storage, and distribution of your product, but excluding Subpart H (Acceptance Activities, 21 CFR 820.80 and 21 CFR 820.86), Subpart I (Nonconforming Product, 21 CFR 820.90), and Subpart O (Statistical Techniques, 21 CFR 820.250).

#### **IV. Conditions of Authorization**

Pursuant to Section 564(e) of the Act, I am establishing the following conditions on this authorization:

##### **Everlywell, Inc. (You) and Authorized Distributor(s)<sup>9</sup>**

- A. Your product must comply with the following labeling requirements under FDA regulations: the intended use statement (21 CFR 809.10(a)(2), (b)(2)); adequate directions for use (21 U.S.C. 352(f)), (21 CFR 809.10(b)(5), (7), and (8)); limitations on the use of the device, including information required under 21 CFR 809.10(a)(4); and any available information regarding performance of the device, including requirements under 21 CFR 809.10(b)(12).
- B. You and authorized distributor(s) must make available with the shipped product the Everlywell COVID-19 Test Home Collection Kit Instructions.
- C. You and authorized distributor(s) must make available on your website(s) the Everlywell COVID-19 Test Home Collection Kit Instructions.
- D. You and authorized distributor(s) must inform authorized laboratories and relevant public health authorities of this EUA, including the terms and conditions herein, and any updates made to your product, or the authorized labeling.
- E. Through a process of inventory control, you and authorized distributor(s) must maintain records of the numbers and locations to which your product is distributed.
- F. You and authorized distributor(s) must maintain customer complaint files on record. You must report to FDA any significant complaints about usability or deviations from the established performance characteristics of the product of which you become aware.
- G. You and authorized distributor(s) are authorized to make available additional information relating to the emergency use of your product that is consistent with, and does not exceed, the terms of this letter of authorization.

---

<sup>9</sup> “Authorized Distributor(s)” are identified by you, Everlywell, Inc., in your EUA submission as an entity allowed to distribute your product.

**Everlywell, Inc. (You)**

- H. You must notify FDA of any authorized distributor(s) of your product, including the name, address, and phone number of any authorized distributor(s).
- I. You must notify FDA of any authorized laboratories designated by Everlywell, Inc. to use your product, including the name, address, and phone number of any authorized laboratories.
- J. You must provide authorized distributor(s) and authorized laboratories with a copy of this EUA and communicate to authorized distributor(s) any subsequent amendments that might be made to this EUA and its authorized accompanying materials.
- K. You may request changes to this EUA for your product, including to the Scope of Authorization (Section II in this letter) or to the authorized labeling, including requests to make available additional authorized labeling specific to an authorized distributor. Such additional labeling may use another name for the product but otherwise must be consistent with the authorized labeling, and not exceed the terms of authorization of this letter. Any request for changes to this EUA should be submitted to the Division of Microbiology (DMD)/Office of Health Technology 7 (OHT7)-Office of In Vitro Diagnostics and Radiological Health (OIR)/Office of Product Evaluation and Quality (OPEQ)/Center for Devices and Radiological Health (CDRH) and require appropriate authorization from FDA prior to implementation.
- L. You must comply with the following requirements pursuant to FDA regulations: 21 CFR 820 Subpart H (Acceptance Activities, 21 CFR 820.80 and 21 CFR 820.86), Subpart I (Nonconforming Product, 21 CFR 820.90), and Subpart O (Statistical Techniques, 21 CFR 820.250).
- M. You must have lot release procedures and the lot release procedures, including the study design and statistical power, must ensure that the kits released for distribution have the clinical and analytical performance claimed in the authorized labeling.
- N. If requested by FDA, you must submit lot release procedures to FDA, including sampling protocols, testing protocols, and acceptance criteria, that you use to release lots of your product for distribution in the U.S. If such lot release procedures are requested by FDA, you must provide it within 48 hours of the request.
- O. You must have a process in place to track adverse events, including any occurrence of false results with your product, and report to FDA pursuant to 21 CFR Part 803. Serious adverse events, especially unexpected biosafety concerns, should immediately be reported to DMD/OHT7-OIR/OPEQ/CDRH (via email: [CDRH-EUA-Reporting@fda.hhs.gov](mailto:CDRH-EUA-Reporting@fda.hhs.gov)).
- P. You must submit to FDA a summary report within 30 calendar days of authorization summarizing the results of any testing performed using anterior nasal swab specimens

collected with the Everlywell COVID-19 Test Home Collection Kit during that timeframe and stratified by age group, including how many kits were requested and sent for home collection to individuals, how many kits were distributed and returned according to the instructions, how many specimens had to be rejected during accession and the main reasons for rejection, and the positivity rate for the Everlywell COVID-19 Test Home Collection Kit. In addition, for kits provided for specimen collection from very young children (2 to 4-year-olds), you should solicit post-collection usability feedback from parents/guardians performing collection to further assess the ease of use of the kit in this age group. Thereafter, monthly reporting must continue until FDA informs you that the cumulative data submitted within the monthly reports has sufficiently assessed updates made to your collection kit.

### **Authorized Laboratories**

- Q. Authorized laboratories testing nasal swab specimens self-collected using the using the Everlywell COVID-19 Test Home Collection Kit must follow the Receiving and Processing Everlywell Samples standard operating procedure when accepting specimens for testing.
- R. Authorized laboratories using your product must use it only in conjunction with COVID-19 in vitro diagnostic (IVD) molecular tests that are authorized for use with your product.
- S. Authorized laboratories must collect information on the performance of your product and report to DMD/OHT7-OIR/OPEQ/CDRH (via email: [CDRH-EUA-Reporting@fda.hhs.gov](mailto:CDRH-EUA-Reporting@fda.hhs.gov)) and you (via email: [covidsupport@everlywell.com](mailto:covidsupport@everlywell.com) or 512-309-5588) any suspected occurrence of false positive or false negative results linked to use of your product and significant deviations from the established performance characteristics of your product of which they become aware.

### **Everlywell, Inc. (You), Authorized Distributors and Authorized Laboratories**

- T. You, authorized distributors, and authorized laboratories using your product must ensure that any records associated with this EUA are maintained until otherwise notified by FDA. Such records will be made available to FDA for inspection upon request.

### **Conditions Related to Printed Materials, Advertising and Promotion**

- U. All descriptive printed matter, advertising and promotional materials relating to the use of your product shall be consistent with the authorized labeling, as well as the terms set forth in this EUA and the applicable requirements set forth in in section 501(a), (q)(1), and (r) of the Act and FDA implementing regulations.
- V. No descriptive printed matter, advertising or promotional materials relating to the use of your product may represent or suggest that this test is safe or effective for the detection of SARS-CoV-2.

W. All descriptive printed matter, advertising and promotional materials relating to the use of your product shall clearly and conspicuously state that:

- This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA;
- This product has been authorized only for the home collection and maintenance of nasal swab specimens as an aid in detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; and
- The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of medical devices under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

The emergency use of your product as described in this letter of authorization must comply with the conditions and all other terms of this authorization.

#### **V. Duration of Authorization**

This EUA will be effective until the declaration that circumstances exist justifying the authorization of the emergency use of medical devices during the COVID-19 outbreak is terminated under Section 564(b)(2) of the Act or the EUA is revoked under Section 564(g) of the Act.

Sincerely,

---

RADM Denise M. Hinton  
Chief Scientist  
Food and Drug Administration

Enclosure